NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Industry news  «  1  2  3  4  5  » 
found files: 758
»04/12/2007 [Industry news]
SFDA Sends staff to train in US

China Food & Beverage Online reported that from October 30 to November 20 the State Food and Drug Administration (SFDA) sent 20 senior management officials to the US to receive training on the administration of food, drug, and medical devices. Participants in the training program are from the local FDAs of Western China. Chinese management officials began the exchange with a visit to the University of Minnesota to learn about US legal and administrative systems and the education system in medical and pharmaceutical colleges. The participants spoke with Minnesota's health department and visited Medtronic Medical Devices and Thomson Legal & Regulatory. The group then visited the US FDA in Washington, D.C., and Bayer Healthcare in Berkeley, California, to gain insight into US practices in R&D and manufacturing. The training project began this year with the officials of the local FDAs of Western China. The program will continue in 2008, when the SFDA plans to send officials from their administration as well as officials from the local FDAs of Eastern and Middle China....   more»

»30/11/2007 [Industry news]
SFDA clarifies new GMP standards - stricter with emphasis on software

November 30, Bian Zhenjia, the Director of the Drug Safety & Inspection Department of the SFDA, clarified the new version of Good Manufacturing Practice (GMP) standards released October 24. The new standards of drug GMP assessment and inspection will take effect January 1, 2008, replacing the current standards which have been in practice since 1999. According to Bian, the new standards are stricter than the previous version. For example, currently, if a pharmaceutical company has less than 3 serious problems, the company may pass GMP certification as long as the problems are corrected within an appropriate timeframe. However, under the new standards, companies with serious problems will not be pass. Bian also indicated that the new standards will strengthen the inspection of raw material purchases, quality control, and software such as file management systems. The current GMP standards only emphasize inspection of facilities and devices....   more»

»15/12/2007 [Industry news]
China Steps Up Drug Inspections

Top leader vows to stop chemical plants from making drugs China's Vice Premier Wu Yi has announced that Chinese authorities will inspect chemical plants throughout the country to make sure they are not producing pharmaceutical ingredients without authorization. She made the announcement while leading a delegation inspecting a toy factory and other plants in the southern province of Guangdong. Wu Yi said chemical plants producing pharmaceuticals without proper government clearance have been posing a public health risk. In the past year, the reputation of China's manufacturing sector has been tarnished by a series of scandals. Cough syrup made with counterfeit ingredients from China killed dozens of people in Panama a year ago. Last month, a toy made in China and sold in the U.S. was recalled after a researcher in an Australian hospital discovered it contained toxic 1,4-butanediol. Meanwhile, FDA is being pressured to improve its inspections of Chinese pharmaceutical plants that supply the U.S. market....   more»

»12/12/2007 [Industry news]
China issues new recall method, encouraging voluntary drug recalls

China's drug safety watchdog has issued a new drug recall method, which encourages pharmaceutical manufacturers to recall unsafe drugs voluntarily. The regulation, promulgated Monday by the State Food and Drug Administration (SFDA), says that enterprises, which voluntarily recall unsafe drugs, will be subject to lower, or even be exempted from, administrative punishment. Those who are aware of problems with their drugs but fail to issue voluntary recalls, will face heavy fines or even be deprived of drug manufacturing licenses, according to the regulation. "Fines will be three times the value of the recalled drugs," Yan Jiangying, spokeswoman of the SFDA, told a press conference Wednesday...   more»

»14/12/2007 [Industry news]
China and US publish list of co-supervised medical products

China and the United State signed an agreement December 11 strengthening drug and medical device safety. As part of the agreement, the two sides published a list of imported medical products that will be subject to supervision by officials from both countries. China put forward a list of 6 drugs and 2 medical devices imported from the U.S: human insulin, lysine monohydrochloride and lysine lipid (cancer treatment), cefoperazone and its monohydrochloride (antibiotic), paclitaxel (chemotherapy), benzylpenicillin, blood test reagents, and intraocular lenses and heart pacemakers. For these products, the U.S. must provide China with manufacturing facility information, registration information, and news of any recalls. The U.S. Health and Human Services listed 8 drugs and 2 medical devices: gentamycin sulfate (cancer treatment), atorvastatin (for cholesterol), sildenafil (API of Viagra), dietary supplements for erectile dysfunction, human growth hormone, oseltamivir (anti-viral), cefixime, glucose testing papers, and condoms. According to the agreement, Chinese companies manufacturing these products for export to the U.S. must register with the SFDA. This pact is one of a number of agreements signed between the U.S. and China during the Joint Commission on Commerce and Trade held this week in Beijing....   more»

»12/12/2007 [Industry news]
China CROs secure more work

This is a press release dated 12th Dec but refers to contracts signed at end of October China's contracted research organisations (CROs) could finally be set to garner a bigger slice of the research being outsourced by big pharmaceutical firms. At a signing ceremony in Beijing in October, five CROs secured research deals worth more than US$7 million to develop medicines and diagnostics for cancer, cardiovascular diseases and rabies, for leading foreign and domestic drug firms such as Jiangsu Province-based Hengri Medicine, the largest cancer drug manufacturer in China. As well as securing R&D deals, Beijing-based CRO AutekBio Inc also won venture capital of $3 million from the US-based Acorn Campus Ventures. Most of the CROs securing the deals belong to the Alliance of Biotech Outsourcing (ABO), an industry association that consists mainly of companies based in Beijing. According to Zhang Zegong, deputy director of Beijing Pharma and Biotech Center (BPBC) - the organisation that founded the ABO - the total revenue of the eight ABO members is expected to double this year, surpassing 300 million yuan ($40.3 million). Compared with Beijing's emerging players, Shanghai's pharmaceutical CROs are performing even better. The price of shares in WuXi Pharmatech, the largest CRO in China, has risen threefold since it was floated on the New York Stock Exchange just two months ago. Wang Hua, a BPBC analyst, told Chemistry World that while CROs are not new to China, this year is the first time they have attracted leading venture capitalists and stock market investors. Nathan Zhang, president of Beijing-based CRO Sinocro, agreed. 'It seems to me that WuXi Pharmatech became a leading pharmaceutical company without developing a patentable drug of its own.' The deals show that China's pharmaceutical industry can develop soundly despite not having access to the financial resources and market revenues required to develop their own drugs, he adds. But Wang Jingang, president of Beijing-based CRO Cosci Med-Tech, says many Chinese CROs are serving the lower end of the value chain for international pharmaceutical giants by, for example, synthesising cheap pharmaceutical ingredients rather than drugs. Zhang agrees. 'The major problem is China's clinical trial criteria are not consistent with the international rules,' he says. 'But I believe that will change gradually...   more»

»30/12/2007 [Industry news]
300 Million Chinese Market Attracts U.S. Pharmaceutical Industry To China

The American pharmaceutical industry is seeking to reverse the lopsided trade with China in favor of the world's most populous nation. But it will be hard to go against traditional Chinese medicine, which is even gaining popularity in the United States....   more»

»28/12/2007 [Industry news]
Novelos Therapeutics and Lee's Pharmaceutical Sign Exclusive Collaboration Agreement in China

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos signed an exclusive license agreement with Lee's Pharmaceutical (HK) Ltd (which is 30% owned by Sigma-Tau Group through Defiante Farmaceutica Lda) to develop and commercialize in China, including Hong Kong and Macau, as well as in Taiwan, two of Novelos' compounds: NOV-002 for cancer and NOV-205 for hepatitis. NOV-002 is Novelos' lead compound in pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track. Lee's Pharmaceutical ("Lee's Pharm") will be responsible for the cost of all clinical development, regulatory submissions and commercialization of NOV-002 and NOV-205 in China. In addition to upfront and milestone payments, Novelos will receive 20-25% royalties from Lee's Pharm on net sales of NOV-002 and 12-15% royalties on net sales of NOV-205. "I am very pleased to be collaborating with Lee's Pharm, a vibrant public company that has a proven track record of developmental and commercialization expertise in China," said Harry Palmin, President and CEO of Novelos. "The significant royalties allow Novelos greater participation in China's rapidly growing marketplace, particularly in critical disease areas of cancer and hepatitis. This deal also marks the commencement of Novelos' ex-US partnering initiative." "We are excited about the opportunity to work with Novelos on its two exciting compounds NOV-002 and NOV-205," said Dr. Benjamin Li, CEO of Lee's Pharm. "With over 1.7 million people being diagnosed with cancer each year and over 120 million people being infected with hepatitis B virus, both cancer and hepatitis B are major health problems facing China today. Better treatment options are badly needed in those areas and the market potential for innovative and effective treatment will be enormous."...   more»

»03/01/2008 [Industry news]
Alliance Boots and partners receive business license

Beijing Med-Pharm Corporation (NASDAQ: BJGP) today announced that Alliance BMP Limited, a UK-based investment vehicle 80 percent-owned by Alliance Boots plc, and 20 percent-owned by Beijing Med-Pharm, received its business license from the Guangzhou Municipal City Government’s Bureau of Industry and Commerce on December 28, 2007. Effective immediately, Alliance BMP Limited will account for financial results from its 50 percent stake in Guangzhou Pharmaceuticals Corporation (“GP Corp.”), the third largest pharmaceutical wholesaler in China. The accretive transaction is expected to close by the end of January 2008, at which point Beijing Med-Pharm will complete payment for its 20 percent stake in the joint venture and David Gao, Beijing Med-Pharm’s Chief Executive Officer, will commence serving as Chairman of GP Corp. "We are very excited to receive our joint venture business license and complete this critical step in closing the acquisition of the 50 percent stake in GP Corp.,” said Mr. Gao. “GP Corp. is an excellent organization whose operations complement ours well and whose strong position in Guangzhou, one of China’s most important markets for healthcare products, presents significant market penetration opportunities for us.” The transaction involves a total capital investment of RMB 545 million ($74.4 million) in cash in exchange for a 50 percent ownership interest in GP Corp. Gao continued, “We look forward to working closely with GP Corp.’s management to ensure successful cooperation and integration of our organizations. We believe our joint efforts can greatly change the dynamics of China’s pharmaceutical distribution methods, especially in southern China, as we consolidate a fragmented market and enhance efficiency through scale. We look forward to working with GP Corp. as well as Alliance Boots, a proven market leader in Europe, to capitalize on this opportunity.” GP Corp. was founded in 1951 and is a subsidiary of Guangzhou Pharmaceutical Company Ltd. ("GPCL"), a company listed on the Hong Kong and Shanghai exchanges whose ultimate parent is the Municipality of Guangzhou. GPCL will retain ownership of the remaining 50 percent of GP Corp. GP Corp. has grown rapidly in recent years, with annual revenues increasing from RMB 4.4 billion ($565 million) in 2003 to RMB 7.4 billion ($0.9 billion) in 2006. GP Corp. serves more than 12,000 hospitals, pharmacies, and other wholesalers from eight distribution facilities located throughout Guangdong Province and southeast China...   more»

»03/01/2008 [Industry news]
Experts agree global language of TCM

The country's first ever set of standard terminologies for traditional Chinese Medicine (TCM) in both Chinese and English was published on Friday in a bid to further promote the practice around the world. Compiled by the World Federation of Chinese Medicine Societies (WFCMS), the publication contains 6,500 terms covering 21 categories including basic theories, disease, acupuncture, medical treatments and formulas. This is a pioneering undertaking and a milestone for the promotion of TCM use globally, said Wang Kui, a division leader with the WFCMS and head of a team of about 200 TCM specialists from 68 countries and regions around the world that agreed the terms. They will be recommended as the international standard for 174 WFCMS member societies in 55 countries and regions when it comes to education, practice, research and information exchange regarding TCM, Wang said. At a time when TCM is becoming increasingly popular around the world, this publication will meet the growing needs of practitioners for a common language, he said. Over the next two years, a further 1,500 to 3,500 terms will be added in a total of five to 10 languages, Wang said. It is important that standards are set for the safe and effective use of TCM so that it can benefit people around the world, Li Daning, deputy director-general of the State Administration of TCM told China Daily. <...   more»

»11/01/2008 [Industry news]
Tiantan Biological Products increase share in vaccine research center

Beijing Tiantan Biological Products (SHA: 600161), a leading developer and manufacturer of biologics in China, will increase its investment in the National Engineering Research Center of Innovative Vaccines, becoming the Center's largest shareholder. Beijing Tiantan Biological Products is a GMP-certified manufacturer of vaccines, blood products, and diagnostic supplies. In 2006, vaccines accounted for 81% of Tiantan's total revenue. The National Engineering Research Center of Innovative Vaccine was established in December 2006 as the first national center for the research and development of innovative vaccines....   more»

»13/01/2008 [Industry news]
China approves Blackstone investment in BlueStar

China's economic planning agency has given the green light to Blackstone Group (BX.N: Quote, Profile, Research) to buy 20 percent of chemical maker China National BlueStar (Group) Corp, the agency said on Thursday. The National Development and Reform Commission (NDRC) said on its Web site that it had approved BlueStar's restructuring plan, which would involve selling 20 percent of its enlarged capital to Blackstone, as a strategic investment The agency provided no financial details....   more»

»13/01/2008 [Industry news]
China is stifling biotechnology research with regulations

China is stifling biotechnology research with regulations that deter foreign companies from investing in an industry that grew 30 percent a year from 2000 to 2005, a new study found. Venture capital is also being hampered by intellectual property laws that don't adequately protect innovations from being copied, researchers at the University of Toronto said. Drugs created from biotechnology are among the most expensive prescriptions. They are made with living cells and consist of more complex molecules than traditional chemical compounds. Impediments to growth may put China behind India and other countries in Asia seeking to create a biotechnology hub, and slow the development of new medicines. Sales of biotechnology drugs, which include anemia treatments such as Amgen Inc.'s Aranesp, as well as insulin and human growth hormone, are growing at more than 10 times the pace of chemical compounds....   more»

»09/01/2008 [Industry news]
China Biotech licenses under review

China's biotech sector accounts for just a sliver of its pharmaceutical industry and operates under the cloud of a massive review of licenses issued under a regulator executed last year for accepting bribes. Even so, experts say, Chinese purveyors of genetically engineered drugs and vaccines -- targeting everything from cancer to Alzheimer's -- are growing at a frenzied pace and are likely to become major actors on the world stage....   more»

»07/01/2008 [Industry news]
Study suggests China biotech industry a 'fire-breathing dragon'

A more favorable investment environment is the only thing needed to turn China's growing biotechnology industry into a "fire-breathing dragon," experts said in a new study published on Monday. The study, to be published online by the journal Nature Biotechnology, found that government funding and the return of native scientists trained abroad had created a sector that could benefit the global health industry. However, difficulties attaining venture capital and getting products onto global markets could curb the sector's growth. "There's a very well established health biotechnology sector in China," co-author Peter Singer of Toronto's McLaughlin-Rotman Centre for Global Health said in an interview. "Even though it's a young sector, they already have innovative products on the market." "We liken it to a baby dragon, which is hard to ignore, and, as it grows, becomes increasingly hard to ignore," Singer added. The study highlighted a unique gene therapy product, developed by Shenzhen SiBiono GeneTech Co, which is used in the treatment of head and neck cancers. Other products included the only cholera vaccine available in tablet form, and ongoing work on an HIV vaccine. The study was done through interviews with 22 small- and medium-sized innovative Chinese firms. The researchers found that while government funding is provided for research, the private funding needed to take a product to the global market was lacking partly due to regulatory barriers, and concerns over quality control and intellectual property rights. Lead author Sarah Frew, research associate at McLaughlin Rotman, said there was also some risk aversion among investors. "It's a bit of a chicken and an egg situation," said Frew. "Investors aren't investing necessarily in the Chinese biotech sector because it's still a risky sector and it's still a bit unknown, so they're waiting to see the front-runners, but the front-runners can't globalize their products without further investment." Despite the challenges, the study sees the Chinese innovative biotech industry, which makes up less than 1 percent of China's biopharmaceutical sector, as one that will move to the world stage within the next five years....   more»

»20/01/2008 [Industry news]
TCM Success in cancer treatments

Many hepatocellular carcinoma (HCC) patients in China may be treated with Traditional Chinese medicine (TCM). Some say it works, others doubt its effectiveness. These stated that a research group in China had found TCM can down-regulate the expression of PTEN in HCC, which may suppress tumor cell growth and regulate tumor cell invasion and metastasis...   more»

»18/01/2008 [Industry news]
China's long-awaited healthcare reform plan to be publicized in March

China's long-awaited reform plan for its failing healthcare system will be released in March shortly after the top legislature's annual session, said Health Minister Chen Zhu...   more»

»16/01/2008 [Industry news]
TCM trial aimed to help prevent diseases

Two traditional Chinese medicine hospitals yesterday announced a pilot program of TCM-based health advice to prevent diseases rather than treat them. If the move in the TCM hospitals of Shuguang and Yueyang in Shanghai, is a success, the service will be expanded to more district-based hospitals and neighborhood health centers, officials from Shanghai Health Bureau said. "Compared with Western medicine, traditional Chinese medicine has its advantages in disease prevention and health care. The new service, which is called treatment before developing disease, can help people adopt a proper lifestyle, arouse awareness about health protection and avoid developing severe syndromes in the future," said Xu Jianguang, director of Shanghai Health Bureau. The new service will provide health checkups and diagnosis from the TCM aspect and give medical and non-medical treatments as necessary....   more»

»17/01/2008 [Industry news]
Outsourcing to grow in life sciences industry

The life sciences industry will see much more outsourcing overseas and domestically in 2008 as it focuses on reducing expenses to keep expanding, according to a new report. Both pharmaceutical giants and emerging biotechnology companies will likely rely on the practice for everything from research and development to clinical trials and manufacturing, according to IDC's Health Industry Insights in Framingham, Mass. The conclusion is one of the firm's many predictions for the industry in 2008. Singapore is among ideal places for outsourcing, according to the report, because the country has strong intellectual property protections and has dedicated significant investment into creating a large biotechnology industry presence. India is also seen as an increasingly viable alternative for research and development outsourcing through lower-cost resources and trained researchers who could work in the country at a fraction of the cost. China has been slow to attract life sciences investment due to concerns about intellectual property, according to the report, but the country has attracted many international companies seeking to outsource clinical trials or take advantage of the company's emerging domestic market. Health Industry Insights also predicts that manufacturing will increasingly be outsourced in order to increase efficiency and expand without incurring extra costs....   more»

»15/01/2008 [Industry news]
Tsinghua to cooperate with MIT on brain research

China's Tsinghua University has recently signed a cooperative agreement with the McGovern Institute for Brain Research (MIBR) at the U.S.-based Massachusetts Institute of Technology (MIT) for a joint neuroscience research program. The program will promote advances in basic neuroscience research that can be applied to the study of the human brain, as well as devastating brain diseases and mental disorders, according to the agreement....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.